Blocking Superantigen-Mediated Diseases: Challenges and Future Trends

Table 1

MHC Ⅱ binding sites and SAgs stimulating specific T cells with TCR Vβ.

SAgs	Group (new)	MHC binding site	Human TCR Vβ	References
SEB	I	α	Vβ1, 3, 6, 12, 13.2, 15, 17, 20	[2, 48–53]
SEC	I	α	Vβ3, 12, 13.2, 14, 15, 17, 20	[48, 49, 52, 53]
SSA	I	α	Vβ1,2,3,5.2,12,15,17,18,19	[53–56]
SElU	I	α	Vβ13.2/14	[9, 56]
SElZ	I	NK	NK	—
SpeA	I	α	Vβ2,12,13,14,15	[9, 52, 53, 56]
SEG	I	α	Vβ3, 12, 13, 14, 15	[48, 49, 55]
SElR	I	α	Vβ3/11/12/13.2/14	[9, 55, 56]
SEH	II	α + β	Vβ6.7,8	[48, 55, 56]
SElW	II	NK	NK	—
SElN	II	α + β	Vβ7, 8, 9, 17	[9, 49, 55]
SElO	II	α + β	Vβ5, 7, 22	[9, 49, 55]
SED	II	α + β	Vβ1, 3, 5, 6,7, 8, 9, 12, 14	[48, 49, 53, 55]
SElP	II	α + β	Vβ5.1/6/8/16/18/21.3	[9, 55, 56]
SEA	II	α + β	Vβ1, 5, 6, 7, 9,15, 16, 18, 21, 22, 24	[48, 49, 52, 53, 55]
SEE	II	α + β	Vβ5, 6, 8, 9, 13, 16, 18, 21	[48, 49, 52, 53]
SpeH	III	NK	Vβ9.1,12.6,23.1	[56]
SpeI	III	β	Vβ18.1	[56–58]
SElL	III	α + β	Vβ1, 5.1, 5.2, 5.3, 7.1, 16, 22, 23	[9, 55, 56]
SEQ	III	α + β	Vβ6.7, 21.3	[9, 55, 56]
SEK	III	β	Vβ1, 5.1, 5.2, 6.7	[9, 55, 56]
SEI	III	β	Vβ1, 5, 6, 23	[48, 49, 55]
SElV	III	α + β	Vβ6/18/21	[9, 55, 56]
SElM	III	α + β	Vβ6, 8, 9, 18, 21	[9, 49, 55]
SpeK	IV	β	NK	[56]
SpeL	IV	β	NK	[56]
SpeG	IV	β	Vβ2.1,4.1,6.9,9.1,12.3	[56, 59]
SpeJ	IV	β	Vβ2.1	[56]
SpeC	IV	β	Vβ2.1	[52, 53, 56]
SElX	V	NK	Vβ1/6/8/21	[9, 56]
TSST-1	V	α	Vβ2	[9, 49, 52, 53]
SElY	V	NK	NK	[9]
SElT	V	α	NK	[9]
SmeZ	V	NK	Vβ2,7, 4, 8	[56]